Showing results (1271-1280 of 1,436) with videos related to

Sort By:
Pageof 144
British Journal of Haematology|August 19, 2011
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemiaPamela S Becker, Hagop M Kantarjian, Frederick R Appelbaum, et al.
Plos One|December 3, 2014
Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia modelJohnnie J Orozco, Ethan R Balkin, Ted A Gooley, et al.
Haematologica|September 30, 2021
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patientsJennifer R Brown, John C Byrd, Paolo Ghia, et al.
Ecography|February 28, 2015
The influence of interspecific interactions on species range expansion ratesJens-Christian Svenning, Dominique Gravel, Robert D Holt, et al.
Leukemia & Lymphoma|March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinionSteven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Blood|September 30, 2009
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndromeJohn M Pagel, Theodore A Gooley, Joseph Rajendran, et al.
Haematologica|October 5, 2019
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasiaPhuong Vo, Ted A Gooley, Joseph G Rajendran, et al.
Plos One|April 10, 2015
Preterm prelabor rupture of membranes and outcome of very-low-birth-weight infants in the German Neonatal NetworkKathrin Hanke, Annika Hartz, Maike Manz, et al.
Blood|August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park, Jaideep Shenoi, John M Pagel, et al.
American Journal of Hematology|April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphomaVictor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.
Pageof 144